GKOS - Despite a slower Q2 Needham sees medtech market growing 7% in 2023

2023-09-04 12:21:00 ET

Needham sees the medtech sector growing by 7% in 2023 versus 5.7% last year, despite slowed growth in Q2, helped by double-digit growth in certain cardiology categories.

The investment bank noted that medtech growth slowed slightly in Q2, expanding by only 8.3% compared with 8.9% in Q1, but still beat its Q2 forecast of 5%. And despite forecasting a 7% increase for 2023, the bank sees growth slipping to 5.3% in 2024.

Needham added that AtriCure ( ATRC ) and Alcon ( ALC ) remain their top ranked companies in the sector, followed by Alphatec ( ATEC ), Glaukos ( GKOS ) and SI-BONE ( SIBN ).

For 2023, Needham sees electrophysiology achieving the highest growth, with worldwide sales climbing 14% to $8.73B led by Boston Scientific ( NYSE: BSX ), which is expected to see a 27% increase, followed by Johnson & Johnson ( JNJ ) at 17%. J&J should remain the dominant player, holding an estimated 49.8% of the market, with Abbott ( ABT ) in second place at 24.5%.

Despite a 14% jump in 2023, Needham sees growth slowing for the electrophysiology market in 2024 and 2025 to 12% and 11%, respectively.

Worldwide sales of transcatheter aortic valve replacement, or TAVR, devices are expected to grow by 10% in 2023, on a constant currency basis, to $6.74B. Abbott is expected to score the biggest gains, with sales up 26%, followed by Boston Scientific at 16%. As for market share, Edwards ( EW ) should continue to hold the No. 1 position with 57.9%, with Medtronic ( MDT ) at No. 2 with 28.5%.

Needham expects TAVR sales to grow by  10% in 2024 and 11% in 2025.

On the flip side, the bank expects the cardiac rhythm management and stent markets to show the least growth this year, with sales for CRM devices expected to rise by only 3% in 2023. Growth is then seen slowing to only 2% in 2024 and 1% in 2025, on a constant currency basis.

Worldwide sales growth for drug-eluting stents is expected to be even worse. Needham sees sales of the devices increasing by only 1% for 2023 on a constant currency basis, followed by a decline of 1% in 2024 and zero growth in 2025.

Despite slowing sales of CRM and stent devices, the cardiology market as a whole saw sales grow by 9.8% during Q2 compared with 8.1% in Q1. Needham now sees sales climbing 7.2% in 2023, help by TAVR and electrophysiology devices, compared with last year’s growth of 6.1%.

Meanwhile, sales of contact lens products have been slowing. The market posted growth of 7.8% in Q2 versus 10.7% in Q1. Needham is now estimating growth of 8.4% for 2023, compared with 8.6% in 2022. Growth is seen as sliding to 5.1% in 2024 and 4.7% in 2025.

The orthopedic device market also appears to be a bit choppy. Worldwide sales of the devices, which include artificial joints, increased by 7.1% in Q2, helped by a 10% increase in knee replacements, but still lower than the 10.3% jump seen in Q1. Needham now sees the sales growing by 7.2% in 2023 versus 5.3% in 2022.

More on medtech:

• JPMorgan says time to buy MedTech based on past
• Medtech set for banner year after significant boost in H1 device approvals
• Morgan Stanley bullish on SI-Bone, downgrades Stevanato, Integra, Agiliti
• Goldman Sachs sees rays of hope in underperforming health sector

For further details see: